RiverVest Venture Partners is a venture capital firm that focuses on building life science companies within the biopharma and medical device sectors. Their strategy involves identifying promising research and technology, then partnering with entrepreneurs to found and fund companies that develop novel therapies and medical devices to address significant unmet patient needs and deliver strong returns to investors.
62% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Their most common stage is series-b (50% of deals). Average disclosed round size is $84.1M (across 8 rounds with reported amounts).
Portfolio
8
Fund Size
$1.6B
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Sparrow Pharmaceuticals | Series B | $95M | Sep 2025 |
 Atalanta Therapeutics | Series B | $75M | Jan 2025 |
 Bluejay Therapeutics | Series C | $182M | May 2024 |
 Avalyn Pharma Inc. | Series C | $175M | Sep 2023 |
 Standard Bariatrics | Series B | $35M | Jun 2021 |
 Reneo Pharmaceuticals | Series A | $50M | May 2019 |
 VentureMed Group | Series B | $15M | Aug 2017 |
 Otonomy, Inc. | Series C | $45.9M | Sep 2013 |
Top Co-Investors
Last updated: 16 April 2026